Rua Bioscience

Rua is a New Zealand cannabis pharmaceutical company that is aiming to be a leading producer of cannabinoid derived medicines. The Company was established in 2017 in part to support local economic development in the Tairawhiti (East Coast) region, and is a pioneer in the New Zealand medicinal cannabis sector. It was the first company in New Zealand to obtain a licence to cultivate cannabis for research purposes. Rua will operate in the research, cultivation, extraction and manufacturing parts of the medicinal cannabis supply chain.


Company Details

Registered Office: 1 Commerce Place, Awapuni, Gisborne 4071
Postal Address: 1 Commerce Place, Awapuni, Gisborne 4071
Telephone: +64-6-390-6938
Facsimile: n/a
Website: www.ruabio.com
First Listed: 22/10/2020
Balance Date: 30 June
AGM: 12/10/2022

Directors and Executives

Tony Barclay
Independent Director
Panapa Ehau
Executive Director
Teresa Farac-Ciprian Independent Non-Executive Director
Brett Gamble
Non-Executive Director
Paul Naske
Chief Executive Officer
Anna Stove
Chair
Hamish White
Chief Financial Officer

Announcements

Title Date Type
Updated Quotation Notice - Rua Bioscience Rights (“RUARA”) Tue, Nov 19 2024 05:06 pm OFFER
Closing date of rights offer extended due to hikoi Tue, Nov 19 2024 04:05 pm OFFER
Revenue continues to grow strongly Mon, Nov 18 2024 08:30 am MKTUPDTE
Rights Offer Opening Thu, Nov 14 2024 02:55 pm OFFER
Rights Offer Frequently Asked Questions (FAQs) Mon, Nov 11 2024 03:37 pm MKTUPDTE
Quotation Notice - Rua Bioscience Limited Rights (“RUARA”) Wed, Nov 06 2024 02:43 pm OFFER
Rua announces details of capital raise Wed, Nov 06 2024 12:42 pm OFFER
Results of 2024 Annual Shareholders' Meeting Mon, Nov 04 2024 03:49 pm MEETING
AMENDED ASM presentation Mon, Nov 04 2024 01:57 pm MEETING
Rua Bioscience ASM presentation and Speeches Mon, Nov 04 2024 09:21 am MEETING

Major Holdings Announcements

Date Name No. Held % Current
22/12/22 Michael John Wilding 8,509,556 - 5.39
18/03/22 Hikurangi Enterprises Limited 8,132,620 - 5.43
17/03/22 Hikurangi Bioactives Limited Partne 4,000,000 12.58 2.67
22/10/20 Tailorspace Capital Limited, Tailor 11,129,375 - 7.95
22/10/20 Fang Group Investment Limited and F 23,584,939 - 16.85
22/10/20 Andrew Charles Williams 7,756,838 - 5.54

Director’s Interests Announcements

Date Name No. Held % Details Other
31/05/23 Hamish White 80,895 - - -
17/05/23 Antony George Barclay 50,000 - - -
02/11/21 Paul Naske 159,872 - - -
02/11/21 Rob Mitchell 288,251 - - -
02/11/21 Panapa Ehau 474,224 - - -
02/11/21 Trevor Burt 958,002 - - -
22/10/20 Martin Smith 2,544,732 - - -
22/10/20 Brett Gamble 1,805,914 - - -
22/10/20 Anna Stove 763,896 - - -

Analysts’ Forecasts

No forecasts available

Disclaimer

Data on this page is from BusinessDesk and NZX Ltd for information purposes only. Details are believed to be accurate but no warranty is given as to accuracy, timeliness, reliability or completeness. No person should rely on the contents of the report and all persons should obtain independent professional advice before acting on any information connected with or contained in this report.
Last Updated: 06/06/2023


Markets News

New $100m Icehouse fund for growth companies
Markets

New $100m Icehouse fund for growth companies

Growth-stage venture market at its most 'investor friendly' since 2013 - Icehouse.

Markets

Snowball rolls out alternative fund options

Private equity, private credit and long short equity funds are on offer.

Snowball rolls out alternative fund options
Markets

Genesis: from dirty to desirable

Genesis argues it is undervalued; at least one analyst agrees.

Genesis: from dirty to desirable
Markets Market close

NZ sharemarket rises on back of positive news

The S&P/NZX 50 Index closed at 13,041.9, rising 276.66 points or 2.17%

Graham Skellern 22 Nov 2024
NZ sharemarket rises on back of positive news
Property

Oceania shrinks footprint, prioritises balance sheet

Oceania has divested four aged care facilities in the space of six months.

Gregor Thompson 22 Nov 2024
Oceania shrinks footprint, prioritises balance sheet